Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Learn more about whether QuidelOrtho Corporation or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Lantheus Holdings, Inc. or QuidelOrtho Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Correlation, of course, is not causation. But even skeptical market strategists acknowledge that when a team from Philadelphia wins the Super ...

Worries about tariffs, artificial intelligence and big-cap tech haven't been able to keep U.S. stocks from climbing back to the doorstep of record territory. While Friday's jobs report for January was ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

We recently published a list of 10 Firms Hit Hard in Thursday’s Trading. In this article, we are going to take a look at ...